| Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
|---|
| D001564 |
Benzo(a)pyrene |
Benzo(a)pyrene inhibits the reaction [cobaltous chloride results in increased expression of CA9 mRNA] | decreases reaction|increases expression | 20228066
|
| D001564 |
Benzo(a)pyrene |
Benzo(a)pyrene inhibits the reaction [cobaltous chloride results in increased expression of CA9 protein] | decreases reaction|increases expression | 20228066
|
| D001564 |
Benzo(a)pyrene |
Benzo(a)pyrene results in decreased expression of CA9 mRNA | decreases expression | 20228066
|
| C400082 |
bortezomib |
bortezomib results in decreased expression of CA9 protein | decreases expression | 16061869
|
| D001959 |
Bromates |
Bromates results in decreased activity of CA9 protein | decreases activity | 15664814
|
| C459604 |
candoxin |
candoxin results in decreased expression of CA9 mRNA | decreases expression | 16309724
|
| D002254 |
Carbonates |
Carbonates results in decreased activity of CA9 protein | decreases activity | 15664814
|
| C022842 |
chloric acid |
chloric acid results in decreased activity of CA9 protein | decreases activity | 15664814
|
| D003035 |
Cobalt |
[tungsten carbide binds to Cobalt] which results in increased expression of CA9 mRNA | affects binding|increases expression | 20105288
|
| C018021 |
cobaltous chloride |
Benzo(a)pyrene inhibits the reaction [cobaltous chloride results in increased expression of CA9 mRNA] | decreases reaction|increases expression | 20228066
|
| C018021 |
cobaltous chloride |
Benzo(a)pyrene inhibits the reaction [cobaltous chloride results in increased expression of CA9 protein] | decreases reaction|increases expression | 20228066
|
| C018021 |
cobaltous chloride |
cobaltous chloride results in increased expression of CA9 mRNA | increases expression | 20228066 20105288
|
| C018021 |
cobaltous chloride |
cobaltous chloride results in increased expression of CA9 protein | increases expression | 20228066
|
| D016572 |
Cyclosporine |
Cyclosporine results in decreased expression of CA9 mRNA | decreases expression | 20106945
|
| D004958 |
Estradiol |
Estradiol results in decreased expression of CA9 mRNA | decreases expression | 20106945
|
| D007452 |
Iodates |
Iodates results in decreased activity of CA9 protein | decreases activity | 15664814
|
| C044659 |
molybdate |
molybdate results in decreased activity of CA9 protein | decreases activity | 15664814
|
| D017942 |
Nitric Acid |
Nitric Acid results in decreased activity of CA9 protein | decreases activity | 15664814
|
| C030110 |
oxaliplatin |
oxaliplatin results in decreased expression of CA9 mRNA | decreases expression | 17762391
|
| D010100 |
Oxygen |
Oxygen deficiency results in increased expression of CA9 mRNA | increases expression | 19154183 18924134
|
| D010100 |
Oxygen |
Oxygen deficiency results in increased expression of CA9 protein | increases expression | 19154183
|
| D010100 |
Oxygen |
Tetrachlorodibenzodioxin inhibits the reaction [Oxygen deficiency results in increased expression of CA9 mRNA] | decreases reaction|increases expression | 19154183
|
| D010100 |
Oxygen |
Tetrachlorodibenzodioxin inhibits the reaction [Oxygen deficiency results in increased expression of CA9 protein] | decreases reaction|increases expression | 19154183
|
| D010100 |
Oxygen |
ARNT protein affects the reaction [Oxygen deficiency results in increased expression of CA9 mRNA] | affects reaction|increases expression | 19154183
|
| D010100 |
Oxygen |
Oxygen deficiency results in increased expression of CA9 mRNA | increases expression | 19154183
|
| D010100 |
Oxygen |
Tetrachlorodibenzodioxin inhibits the reaction [Oxygen deficiency results in increased expression of CA9 mRNA] | decreases reaction|increases expression | 19154183
|
| C494474 |
perchlorate |
perchlorate results in decreased activity of CA9 protein | decreases activity | 15664814
|
| C037192 |
potassium periodate |
potassium periodate results in decreased activity of CA9 protein | decreases activity | 15664814
|
| C025349 |
sodium metasilicate |
sodium metasilicate results in decreased activity of CA9 protein | decreases activity | 15664814
|
| C005741 |
sulfamic acid |
sulfamic acid results in decreased activity of CA9 protein | decreases activity | 15664814
|
| D013431 |
Sulfates |
Sulfates results in decreased activity of CA9 protein | decreases activity | 15664814
|
| D013438 |
Sulfhydryl Compounds |
Sulfhydryl Compounds analog binds to and results in decreased activity of CA9 protein | affects binding|decreases activity | 17059166
|
| D013467 |
Sulindac |
Sulindac analog results in decreased expression of CA9 mRNA | decreases expression | 18924134
|
| D013749 |
Tetrachlorodibenzodioxin |
Tetrachlorodibenzodioxin inhibits the reaction [Oxygen deficiency results in increased expression of CA9 mRNA] | decreases reaction|increases expression | 19154183
|
| D013749 |
Tetrachlorodibenzodioxin |
Tetrachlorodibenzodioxin inhibits the reaction [Oxygen deficiency results in increased expression of CA9 protein] | decreases reaction|increases expression | 19154183
|
| D013749 |
Tetrachlorodibenzodioxin |
Tetrachlorodibenzodioxin inhibits the reaction [Oxygen deficiency results in increased expression of CA9 mRNA] | decreases reaction|increases expression | 19154183
|
| C045951 |
tungstate |
tungstate results in decreased activity of CA9 protein | decreases activity | 15664814
|
| C002802 |
tungsten carbide |
[tungsten carbide binds to Cobalt] which results in increased expression of CA9 mRNA | affects binding|increases expression | 20105288
|
| C002802 |
tungsten carbide |
tungsten carbide results in increased expression of CA9 mRNA | increases expression | 20105288
|
| D014638 |
Vanadates |
Vanadates results in decreased activity of CA9 protein | decreases activity | 15664814
|
| Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
|---|
| MESH:D000008 |
Abdominal Neoplasms |
|
Sulindac |
5.29 | 14745880 |
| MESH:D000014 |
Abnormalities, Drug-Induced |
|
Tetrachlorodibenzodioxin |
2.64 | 15322242 11752688 14514962 |
| MESH:D058186 |
Acute Kidney Injury |
|
Sulindac |
4.13 | 7897758 |
| MESH:D055371 |
Acute Lung Injury |
|
Oxygen |
4.34 | 16759491 |
| MESH:D000230 |
Adenocarcinoma |
|
Benzo(a)pyrene |
6.86 | 20127859 20464547 |
| MESH:D000230 |
Adenocarcinoma |
|
Estradiol |
6.86 | 11473722 |
| MESH:D000230 |
Adenocarcinoma |
|
Sulindac |
6.86 | 11910360 |
| MESH:D000236 |
Adenoma |
|
Benzo(a)pyrene |
6.57 | 6695378 |
| MESH:D000236 |
Adenoma |
|
Sulindac |
6.57 | 10223192 |
| MESH:D018248 |
Adenoma, Liver Cell |
|
Tetrachlorodibenzodioxin |
3.17 | 16835633 |
| MESH:D011125 |
Adenomatous Polyposis Coli |
|
Sulindac |
4.42 | 19003578 16460482 11535846 11874996 15623613 17611924 12394442 |
| MESH:D000740 |
Anemia |
|
Tetrachlorodibenzodioxin |
2.76 | 11748828 |
| MESH:D000860 |
Anoxia |
marker/mechanism |
|
| 16954440 |
| MESH:D000860 |
Anoxia |
|
Oxygen |
4.84 | 20872349 |
| MESH:D017544 |
Aortic Aneurysm, Abdominal |
|
Benzo(a)pyrene |
3.87 | 19183758 |
| MESH:D050197 |
Atherosclerosis |
|
Oxygen |
3.68 | 16391483 |
| MESH:D001778 |
Blood Coagulation Disorders |
|
Tetrachlorodibenzodioxin |
2.86 | 12125929 |
| MESH:D001836 |
Body Weight Changes |
|
Tetrachlorodibenzodioxin |
3.58 | 15340226 |
| MESH:D001848 |
Bone Diseases, Developmental |
|
Tetrachlorodibenzodioxin |
2.63 | 15746008 |
| MESH:D001913 |
Bowen's Disease |
|
Sulindac |
5.14 | 11207687 |
| MESH:D001943 |
Breast Neoplasms |
|
Benzo(a)pyrene |
2.87 | 20146248 17474063 |
| MESH:D001943 |
Breast Neoplasms |
|
Cobalt |
2.87 | 15986119 |
| MESH:D001943 |
Breast Neoplasms |
|
Estradiol |
2.87 | 19861407 12948864 17261762 16675129 14630087 17018787 17289903 18497071 |
| MESH:D001943 |
Breast Neoplasms |
|
Oxygen |
2.87 | 17263869 |
| MESH:D001943 |
Breast Neoplasms |
|
Sulindac |
2.87 | 16642371 |
| MESH:D001943 |
Breast Neoplasms |
|
Tetrachlorodibenzodioxin |
2.87 | 20435547 |
| MESH:D002181 |
Candidiasis, Vulvovaginal |
|
Estradiol |
4.25 | 16111702 |
| MESH:D002277 |
Carcinoma |
|
Tetrachlorodibenzodioxin |
2.63 | 16835633 |
| MESH:D006528 |
Carcinoma, Hepatocellular |
|
Estradiol |
1.74 | 16924424 |
| MESH:D002289 |
Carcinoma, Non-Small-Cell Lung |
|
bortezomib |
3.88 | 16052434 |
| MESH:D002294 |
Carcinoma, Squamous Cell |
|
Benzo(a)pyrene |
1.99 | 20419170 |
| MESH:D006332 |
Cardiomegaly |
|
Tetrachlorodibenzodioxin |
2.25 | 16120746 18670907 18850075 |
| MESH:D002471 |
Cell Transformation, Neoplastic |
|
Cyclosporine |
6.10 | 12371664 |
| MESH:D002471 |
Cell Transformation, Neoplastic |
|
Estradiol |
6.10 | 18566989 |
| MESH:D018281 |
Cholangiocarcinoma |
|
Tetrachlorodibenzodioxin |
2.99 | 16835633 |
| MESH:D002779 |
Cholestasis |
|
Cyclosporine |
2.76 | 19486331 |
| MESH:D002972 |
Cleft Palate |
|
Tetrachlorodibenzodioxin |
2.02 | 15340226 8697196 15668235 16354765 12621046 |
| MESH:D003110 |
Colonic Neoplasms |
|
oxaliplatin |
4.29 | 16024531 16510598 16004971 |
| MESH:D003110 |
Colonic Neoplasms |
|
Sulindac |
4.29 | 12458338 12902858 |
| MESH:D015179 |
Colorectal Neoplasms |
|
oxaliplatin |
3.14 | 17695437 18448328 17401013 17594712 17255274 18509181 |
| MESH:D015179 |
Colorectal Neoplasms |
|
Sulindac |
3.14 | 18059344 10666051 11197048 11076880 |
| MESH:D000013 |
Congenital Abnormalities |
|
Tetrachlorodibenzodioxin |
2.88 | 17141729 14669216 |
| MESH:D019465 |
Craniofacial Abnormalities |
|
Tetrachlorodibenzodioxin |
1.25 | 15322242 10048152 20055451 |
| MESH:D017449 |
Dermatitis, Allergic Contact |
|
cobaltous chloride |
3.83 | 11298694 15059100 16823706 |
| MESH:D003924 |
Diabetes Mellitus, Type 2 |
|
Tetrachlorodibenzodioxin |
1.62 | 17107852 |
| MESH:D003928 |
Diabetic Nephropathies |
|
Estradiol |
3.24 | 19279558 |
| MESH:D003930 |
Diabetic Retinopathy |
|
Sulindac |
4.98 | 17621415 12861449 |
| MESH:D056486 |
Drug-Induced Liver Injury |
|
Tetrachlorodibenzodioxin |
1.48 | 20420201 |
| MESH:D004362 |
Drug Toxicity |
|
Tetrachlorodibenzodioxin |
2.61 | 11462148 |
| MESH:D004417 |
Dyspnea |
|
Oxygen |
4.62 | 20016425 |
| MESH:D004487 |
Edema |
|
Tetrachlorodibenzodioxin |
2.20 | 12711302 11000095 |
| MESH:D004489 |
Edema, Cardiac |
|
Tetrachlorodibenzodioxin |
3.69 | 16714409 15322242 18230668 |
| MESH:D016889 |
Endometrial Neoplasms |
|
Estradiol |
2.85 | 19148513 11473722 18566989 |
| MESH:D004715 |
Endometriosis |
|
Sulindac |
8.58 | 15652904 |
| MESH:D004715 |
Endometriosis |
|
Tetrachlorodibenzodioxin |
8.58 | 9294722 10568697 |
| MESH:D004938 |
Esophageal Neoplasms |
|
Benzo(a)pyrene |
4.55 | 16530937 |
| MESH:D004938 |
Esophageal Neoplasms |
|
Sulindac |
4.55 | 12235107 |
| MESH:D005124 |
Eye Abnormalities |
|
Tetrachlorodibenzodioxin |
2.86 | 11564622 |
| MESH:D005234 |
Fatty Liver |
|
Cyclosporine |
2.67 | 19224547 |
| MESH:D005313 |
Fetal Death |
|
Tetrachlorodibenzodioxin |
3.25 | 11858732 |
| MESH:D018221 |
Fibromatosis, Abdominal |
|
Sulindac |
5.27 | 14745880 |
| MESH:D018222 |
Fibromatosis, Aggressive |
|
Sulindac |
4.92 | 19069698 |
| MESH:D005355 |
Fibrosis |
|
Cyclosporine |
7.79 | 12639820 12168785 |
| MESH:D005355 |
Fibrosis |
|
Tetrachlorodibenzodioxin |
7.79 | 20067830 |
| MESH:D005739 |
Gas Poisoning |
|
Oxygen |
5.01 | 20016425 |
| MESH:D005764 |
Gastroesophageal Reflux |
|
Sulindac |
4.81 | 11910360 |
| MESH:D005885 |
Gingival Hyperplasia |
|
Cyclosporine |
4.01 | 8708960 |
| MESH:D006042 |
Goiter |
|
perchlorate |
5.11 | 18801409 |
| MESH:D006058 |
Gonadal Disorders |
|
Tetrachlorodibenzodioxin |
4.38 | 10696789 |
| MESH:D006330 |
Heart Defects, Congenital |
|
Benzo(a)pyrene |
6.08 | 20471113 |
| MESH:D006330 |
Heart Defects, Congenital |
|
Tetrachlorodibenzodioxin |
6.08 | 10048152 11294989 |
| MESH:D006457 |
Hemoglobinuria, Paroxysmal |
|
Cyclosporine |
4.21 | 15720958 |
| MESH:D006470 |
Hemorrhage |
|
Tetrachlorodibenzodioxin |
3.15 | 11000095 |
| MESH:D006529 |
Hepatomegaly |
|
Tetrachlorodibenzodioxin |
2.69 | 12621046 16120746 15340226 |
| MESH:D006558 |
Herpes Genitalis |
|
Estradiol |
4.82 | 15709030 |
| MESH:D019584 |
Hot Flashes |
|
Estradiol |
3.54 | 17088409 |
| MESH:D006869 |
Hydronephrosis |
|
Tetrachlorodibenzodioxin |
3.83 | 8697196 18606429 16959395 15340226 16354765 |
| MESH:D006930 |
Hyperalgesia |
|
oxaliplatin |
4.19 | 17418472 |
| MESH:D006934 |
Hypercalcemia |
|
bortezomib |
5.26 | 18089816 |
| MESH:D006973 |
Hypertension |
|
Cobalt |
8.25 | 17039479 |
| MESH:D006973 |
Hypertension |
|
Cyclosporine |
8.25 | 10903974 |
| MESH:D006973 |
Hypertension |
|
Tetrachlorodibenzodioxin |
8.25 | 18670907 18850075 |
| MESH:D007249 |
Inflammation |
|
Sulindac |
4.88 | 3291741 |
| MESH:D007249 |
Inflammation |
|
Tetrachlorodibenzodioxin |
4.88 | 12200463 12878042 |
| MESH:D007333 |
Insulin Resistance |
|
Estradiol |
2.83 | 16393666 16627594 |
| MESH:D007414 |
Intestinal Neoplasms |
|
Sulindac |
4.45 | 12584176 12663524 12351151 12628509 10213222 10223192 |
| MESH:D007417 |
Intestinal Polyps |
|
Sulindac |
4.79 | 11245490 12394442 |
| MESH:D007569 |
Jaw Abnormalities |
|
Tetrachlorodibenzodioxin |
3.15 | 16580747 |
| MESH:D007638 |
Keratoconjunctivitis Sicca |
|
Cyclosporine |
4.23 | 15604871 |
| MESH:D007674 |
Kidney Diseases |
|
Cyclosporine |
5.54 | 8314463 10903974 18776723 |
| MESH:D007674 |
Kidney Diseases |
|
Estradiol |
5.54 | 15618244 |
| MESH:D007680 |
Kidney Neoplasms |
|
Cyclosporine |
6.71 | 12371664 |
| MESH:D007680 |
Kidney Neoplasms |
|
Estradiol |
6.71 | 15610895 |
| MESH:D015459 |
Leukemia-Lymphoma, Adult T-Cell |
|
bortezomib |
4.99 | 18089816 |
| MESH:D015470 |
Leukemia, Myeloid, Acute |
|
bortezomib |
3.49 | 20471514 |
| MESH:D008105 |
Liver Cirrhosis, Biliary |
|
Sulindac |
4.09 | 12468960 |
| MESH:D008106 |
Liver Cirrhosis, Experimental |
|
Estradiol |
2.19 | 14659978 14716833 |
| MESH:D008106 |
Liver Cirrhosis, Experimental |
|
Tetrachlorodibenzodioxin |
2.19 | 12878042 |
| MESH:D008107 |
Liver Diseases |
|
Sulindac |
2.98 | 16867024 14986274 |
| MESH:D008113 |
Liver Neoplasms |
|
Benzo(a)pyrene |
4.07 | 20195826 21137059 |
| MESH:D008113 |
Liver Neoplasms |
|
Tetrachlorodibenzodioxin |
4.07 | 16984957 |
| MESH:D008114 |
Liver Neoplasms, Experimental |
|
Tetrachlorodibenzodioxin |
1.98 | 12151625 |
| MESH:D008173 |
Lung Diseases, Obstructive |
|
Cobalt |
5.65 | 6434250 |
| MESH:D055370 |
Lung Injury |
|
Oxygen |
4.30 | 18339021 |
| MESH:D008175 |
Lung Neoplasms |
|
Benzo(a)pyrene |
3.33 | 18816296 18520028 18569708 20135361 20064080 6695378 20869020 17053015 20464547 |
| MESH:D008175 |
Lung Neoplasms |
|
Sulindac |
3.33 | 19359593 15713900 |
| MESH:D008175 |
Lung Neoplasms |
|
Tetrachlorodibenzodioxin |
3.33 | 11884234 19555203 |
| MESH:D008223 |
Lymphoma |
|
bortezomib |
4.41 | 16098063 |
| MESH:D016393 |
Lymphoma, B-Cell |
|
bortezomib |
5.12 | 16675587 |
| MESH:D008325 |
Mammary Neoplasms, Experimental |
|
Estradiol |
2.43 | 11408345 11807958 17203775 16891317 |
| MESH:D020149 |
Manganese Poisoning |
|
Estradiol |
4.27 | 19453300 |
| MESH:D008527 |
Medulloblastoma |
|
bortezomib |
4.15 | 19213072 |
| MESH:D008545 |
Melanoma |
|
Sulindac |
2.80 | 16642371 |
| MESH:D008664 |
Metal Metabolism, Inborn Errors |
|
Cyclosporine |
4.58 | 16801185 |
| MESH:D009062 |
Mouth Neoplasms |
|
Benzo(a)pyrene |
3.03 | 16381670 |
| MESH:D009101 |
Multiple Myeloma |
|
bortezomib |
4.34 | 19372569 19112201 19112817 |
| MESH:D017202 |
Myocardial Ischemia |
|
Tetrachlorodibenzodioxin |
2.85 | 12213967 |
| MESH:D015428 |
Myocardial Reperfusion Injury |
|
Estradiol |
3.12 | 16810080 |
| MESH:D009369 |
Neoplasms |
|
Benzo(a)pyrene |
2.07 | 11141357 |
| MESH:D009389 |
Neovascularization, Pathologic |
|
Estradiol |
3.52 | 17289903 |
| MESH:D009402 |
Nephrosis, Lipoid |
|
Cyclosporine |
4.23 | 17954296 |
| MESH:D009404 |
Nephrotic Syndrome |
|
Cyclosporine |
3.11 | 19348381 18481113 |
| MESH:D009421 |
Nervous System Malformations |
|
Estradiol |
8.79 | 11399458 16427766 |
| MESH:D009421 |
Nervous System Malformations |
|
Tetrachlorodibenzodioxin |
8.79 | 14600291 |
| MESH:D019636 |
Neurodegenerative Diseases |
|
Sulindac |
4.10 | 16850258 17266991 |
| MESH:D010051 |
Ovarian Neoplasms |
|
Estradiol |
2.16 | 19401270 |
| MESH:D010146 |
Pain |
|
Sulindac |
3.63 | 3291741 |
| MESH:D010190 |
Pancreatic Neoplasms |
|
Sulindac |
3.28 | 11504793 16820089 |
| MESH:D010382 |
Peliosis Hepatis |
|
Tetrachlorodibenzodioxin |
4.04 | 12520081 |
| MESH:D010437 |
Peptic Ulcer |
|
Sulfhydryl Compounds |
7.02 | 1488453 |
| MESH:D017119 |
Porphyria Cutanea Tarda |
|
Tetrachlorodibenzodioxin |
3.36 | 18163543 |
| MESH:D011230 |
Precancerous Conditions |
|
Cyclosporine |
3.05 | 12371664 |
| MESH:D011297 |
Prenatal Exposure Delayed Effects |
|
Tetrachlorodibenzodioxin |
2.98 | 11896295 11222880 11118676 11399792 |
| MESH:D019048 |
Prostatic Intraepithelial Neoplasia |
|
Estradiol |
3.69 | 20887781 |
| MESH:D011471 |
Prostatic Neoplasms |
|
Benzo(a)pyrene |
3.18 | 17292933 |
| MESH:D011471 |
Prostatic Neoplasms |
|
Estradiol |
3.18 | 16740699 |
| MESH:D011565 |
Psoriasis |
|
Cyclosporine |
2.16 | 16882103 |
| MESH:D011658 |
Pulmonary Fibrosis |
|
Cobalt |
3.92 | 6434250 |
| MESH:D012128 |
Respiratory Distress Syndrome, Adult |
|
Oxygen |
4.31 | 18339021 17627322 |
| MESH:D015619 |
Respiratory System Abnormalities |
|
Tetrachlorodibenzodioxin |
3.64 | 18990726 |
| MESH:D012878 |
Skin Neoplasms |
|
Benzo(a)pyrene |
5.15 | 10029692 19755658 |
| MESH:D012878 |
Skin Neoplasms |
|
Tetrachlorodibenzodioxin |
5.15 | 16192470 |
| MESH:D013274 |
Stomach Neoplasms |
|
Benzo(a)pyrene |
1.55 | 2093021 20155912 |
| MESH:D013398 |
Sudden Infant Death |
|
Oxygen |
5.33 | 12563064 |
| MESH:D013959 |
Thyroid Diseases |
|
Tetrachlorodibenzodioxin |
3.69 | 12697716 |
| MESH:D013978 |
Tibial Fractures |
|
Estradiol |
4.47 | 19048282 |
| MESH:D001749 |
Urinary Bladder Neoplasms |
|
Benzo(a)pyrene |
2.10 | 17053015 |
| MESH:D014594 |
Uterine Neoplasms |
|
Sulindac |
4.40 | 18645019 |
| MESH:D014605 |
Uveitis |
|
Cyclosporine |
3.77 | 1336536 |
| MESH:D054079 |
Vascular Malformations |
|
Tetrachlorodibenzodioxin |
4.38 | 12125929 |
| MESH:D019282 |
Wasting Syndrome |
|
Tetrachlorodibenzodioxin |
4.04 | 15886252 |
| MESH:D014985 |
Xerophthalmia |
|
Cyclosporine |
4.23 | 17120751 |